<DOC>
	<DOCNO>NCT01833039</DOCNO>
	<brief_summary>The purpose study provide patient relapse refractory Mantle Cell Lymphoma ( MCL ) early access investigational medication call ibrutinib ( PCI-32765 ) collect safety information drug .</brief_summary>
	<brief_title>An Open Label Treatment Use Protocol Ibrutinib Subjects With Relapsed Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<criteria>Patients , 18 year age old , Mantle Cell Lymphoma relapse refractory disease prior therapy eligible . Patients eligible enrollment ongoing clinical study ibrutinib eligible . Patients previously treat ibrutinib eligible . Patients enrol another interventional clinical study therapeutic intent eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Ibrutinib</keyword>
</DOC>